XNASANGO
Market cap353mUSD
Dec 24, Last price
9.01USD
1D
-1.92%
1Q
17.43%
Jan 2017
-48.49%
Name
AngioDynamics Inc
Chart & Performance
Profile
AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and vascular access; and for use in oncology and surgical settings in the United States and internationally. The company provides NanoKnife ablation systems for the surgical ablation of soft tissues; solero microwave tissue ablation systems; and radiofrequency ablation products for ablating solid cancerous or benign tumors. It also offers BioSentry tract sealant systems, IsoLoc Endorectal Balloon's, alatus vaginal balloon packing systems, angiographic catheters, guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits. In addition, the company provides endovascular therapies products in the areas of thrombus management, atherectomy, peripheral products (Core), and venous insufficiency. Additionally, the company offers peripherally inserted central catheters, midline catheters, implantable ports, dialysis catheters, and related accessories and supplies that are used primarily to deliver short-term drug therapies, such as chemotherapeutic agents and antibiotics, into the central venous system under the BioFlo, BioFlo Midline, BioFlo PICC, Xcela PICC, PASV, BioFlo Port, SmartPort, Vortex, LifeGuard, BioFlo DuraMax, and DuraMax names. It sells and markets its products to interventional radiologists, interventional cardiologists, vascular surgeons, urologists, interventional and surgical oncologists, and critical care nurses directly, as well as through distributor relationships. The company was founded in 1988 and is headquartered in Latham, New York.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|---|
2024‑05 | 2023‑05 | 2022‑05 | 2021‑05 | 2020‑05 | 2019‑05 | 2018‑05 | 2017‑05 | 2016‑05 | 2015‑05 | |
Income | ||||||||||
Revenues | 303,914 -10.28% | 338,752 7.13% | 316,219 8.66% | |||||||
Cost of revenue | 324,710 | 338,641 | 314,978 | |||||||
Unusual Expense (Income) | ||||||||||
NOPBT | (20,796) | 111 | 1,241 | |||||||
NOPBT Margin | 0.03% | 0.39% | ||||||||
Operating Taxes | (7,289) | (1,995) | (3,402) | |||||||
Tax Rate | ||||||||||
NOPAT | (13,507) | 2,106 | 4,643 | |||||||
Net income | (184,349) 251.53% | (52,442) 97.54% | (26,547) -15.85% | |||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | 1,171 | 2,683 | ||||||||
BB yield | -0.31% | -0.35% | ||||||||
Debt | ||||||||||
Debt current | 1,975 | 1,922 | 8,783 | |||||||
Long-term debt | 7,878 | 56,450 | 29,703 | |||||||
Deferred revenue | ||||||||||
Other long-term liabilities | 12,139 | 4,569 | 12,901 | |||||||
Net debt | (66,203) | 26,565 | 9,661 | |||||||
Cash flow | ||||||||||
Cash from operating activities | (28,158) | 78 | (7,194) | |||||||
CAPEX | (2,518) | (4,352) | (4,297) | |||||||
Cash from investing activities | 123,717 | (9,746) | (19,307) | |||||||
Cash from financing activities | (64,248) | 25,420 | 7,683 | |||||||
FCF | 13,130 | (9,177) | (13,035) | |||||||
Balance | ||||||||||
Cash | 76,056 | 44,620 | 28,825 | |||||||
Long term investments | (12,813) | |||||||||
Excess cash | 60,860 | 14,869 | 13,014 | |||||||
Stockholders' equity | (399,184) | (215,196) | (156,676) | |||||||
Invested Capital | 622,823 | 667,878 | 627,099 | |||||||
ROIC | 0.33% | 0.75% | ||||||||
ROCE | 0.02% | 0.26% | ||||||||
EV | ||||||||||
Common stock shares outstanding | 40,181 | 39,480 | 39,009 | |||||||
Price | 6.31 -33.30% | 9.46 -51.81% | 19.63 -15.10% | |||||||
Market cap | 253,542 -32.11% | 373,484 -51.23% | 765,755 -13.62% | |||||||
EV | 187,339 | 400,049 | 775,416 | |||||||
EBITDA | 6,916 | 30,984 | 30,590 | |||||||
EV/EBITDA | 27.09 | 12.91 | 25.35 | |||||||
Interest | 2,702 | 688 | ||||||||
Interest/NOPBT | 2,434.23% | 55.44% |